A Phase II/III Study of Dalotuzumab (MK-0646) Treatment in Combination With Cetuximab and Irinotecan for Patients With Metastatic Colorectal Cancer

Trial Profile

A Phase II/III Study of Dalotuzumab (MK-0646) Treatment in Combination With Cetuximab and Irinotecan for Patients With Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 15 Jan 2017

At a glance

  • Drugs Dalotuzumab (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Sep 2015 Primary endpoint (Overall survival) has not been met according to the results published in the Journal of the National Cancer Institute.
    • 01 Sep 2015 Primary endpoint (Progression-free survival) has not been met according to the results published in the Journal of the National Cancer Institute.
    • 01 Sep 2015 Interim results (n = 538) published in the Journal of the National Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top